免疫检查点
免疫疗法
癌症
无容量
医学
癌症研究
细胞毒性T细胞
癌症免疫疗法
黑色素瘤
肺癌
免疫学
免疫系统
肿瘤科
生物
内科学
体外
生物化学
作者
Alex Friedlaender,Alfredo Addeo,Giuseppe Luigi Banna
出处
期刊:ESMO open
[Elsevier]
日期:2019-01-01
卷期号:4: e000497-e000497
被引量:72
标识
DOI:10.1136/esmoopen-2019-000497
摘要
Currently, the programmed death-1/programmed death ligand-1 and the cytotoxic T-lymphocyte-associated protein 4 are the two commonly targeted immune-checkpoint inhibition pathways. These drugs have significantly improved the prognosis of many cancer types. While immune-checkpoint inhibitors have revolutionised the treatment of many cancer types, the majority of patients still progress. Several treatment strategies have been pursued to improve current results. One approach is to combine two checkpoint inhibitors, currently with promising results in melanoma, renal cell carcinoma and a subset of non-small-cell lung cancer patients. The identification of new checkpoint targets could allow the field of immuno-oncology to evolve further. We will discuss one of the most promising immune-checkpoint targets currently under investigation, the T-cell immunoglobulin and mucin domain-3.
科研通智能强力驱动
Strongly Powered by AbleSci AI